"Chai Discovery, an AI startup founded in 2024, is one such company. In a little over 12 months, its young co-founders have managed to raise hundreds of millions of dollars and rally the backing of some of Silicon Valley's most influential investors, making it one of the flashiest firms in a growing industry. In December, the company completed its series B, bringing in an additional $130 million and a valuation of $1.3 billion."
"Last Friday, Chai also announced a partnership with Eli Lilly, a deal in which the pharmaceutical giant will use the startup's software to help develop new medicines. Chai's algorithm, called Chai-2, is designed to develop antibodies-the proteins necessary to fight illnesses. The startup has said it hopes to serve as a kind of "computer-aided design suite" for molecules. It's a critical moment for Chai's particular field."
"The startup's deal was announced shortly before Eli Lilly said it would also collaborate with NVIDIA on a $1 billion partnership to create an AI drug discovery lab in San Francisco. This "co-innovation lab," as it's being called, will combine big data, compute resources, and scientific expertise, all in an attempt to accelerate the speed of new medicine development."
Chai Discovery, founded in 2024, has rapidly raised hundreds of millions in funding and reached a $1.3 billion valuation after a Series B round. The startup announced a partnership with Eli Lilly to use its Chai-2 algorithm to develop antibodies and aims to function as a computer-aided design suite for molecular discovery. Eli Lilly also announced a separate $1 billion collaboration with NVIDIA to build an AI drug discovery lab combining big data, compute resources, and scientific expertise. The industry contains both skeptics and believers regarding the impact of these new technologies.
Read at TechCrunch
Unable to calculate read time
Collection
[
|
...
]